Biotech Values

[DewDiligence]

NVS Reports 3Q10 Results

[Generic Lovenox sales during the 69-day period from the 7/23/10 launch through 9/30/10 were $292M. This is an annualized run rate of $1.55B, consistent with the assertion I made many moons ago that NVS/MNTA’s Lovenox will be the largest-selling generic drug of all time. Although the 3Q10 sales figure was presumably boosted by wholesale channel stocking, this one-time effect was offset to some degree by the ramp-up of NVS' market share from 35-40% at launch to the current 45%+.]

http://www.novartis.com/downloads/investors/sales-results/Q3-2010-media-release_EN.pdf

Sandoz achieved strong overall sales growth of 18% (+23 % cc) in the third quarter versus the same period in 2009, driven by strong performance in North America, Europe, emerging markets and biosimilars. Much of this growth was driven by the success Sandoz has had in gaining market share in injectables and biosimilars. Newly launched products, such as enoxaparin, losartan, and tacrolimus, have been key in driving year-to-date growth. Of particular note is the third quarter launch of enoxaparin, the first-to-market generic version of the anti-thrombotic drug Lovenox, which was the most successful injectables launch in the US ever.